Homepage
Author:
Ensysce Biosciences
Posted Date:
May 15, 2026
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Ensysce Biosciences
May 15, 2026
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences
May 12, 2026
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Ensysce Biosciences
May 8, 2026
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences
April 16, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Ensysce Biosciences
April 7, 2026
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Ensysce Biosciences
March 31, 2026
Ensysce Biosciences Initiates Live “Ask Me Anything” (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences
March 4, 2026
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Ensysce Biosciences
March 3, 2026
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences
February 25, 2026
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences
February 23, 2026
1
2
Next
